Fludarabine
Esophageal Adenocarcinoma
Dispatch BiotherapeuticsSmall moleculePhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 73/ 100
Competitive context
51 Active assets in the Esophageal Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin I-Mab Biopharma US Limited | Phase 3 | BB |
Capecitabine I-Mab Biopharma US Limited | Phase 3 | B |
Pyrotinib BeOne Medicines | Phase 3 | B |
Tislelizumab BeOne Medicines | Phase 3 | B |
rc48-adc BeOne Medicines | Phase 3 | B |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →